UK Markets open in 6 hrs 10 mins

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed price. Currency in EUR
Add to watchlist
18.53-0.08 (-0.46%)
At close: 05:35PM CEST
Full screen
Loading interactive chart…
  • Motley Fool

    Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

    On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.

  • Reuters

    Grifols shares soar as plasma collection reaches pre-pandemic levels

    Spanish pharmaceuticals company Grifols' shares soared on Friday as the company reported the volumes of blood plasma it collected reached pre-pandemic levels in the first quarter. Grifols' collection of the blood plasma it uses to make haematology medicines, collapsed during the COVID-19 pandemic when its collection centres around the world were closed, hitting its net profit, which fell 70% in 2021. As a result Grifols lost around 50% of its market value since the COVID-19 pandemic started in 2020 when its shares were trading at record levels.

  • Reuters

    Grifols' profit slides 70% on blood plasma supply disruption

    BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols' full-year net profit fell 70% to 183 million euros ($204.70 million) as the COVID-19 pandemic continued to disrupt supplies of the blood plasma it uses to make medicines. Grifols said the pandemic had a negative impact of 503 million euros on core earnings, mainly because of lower collection of blood plasma, which was down 4% year on year, though there was an improvement in the fourth quarter. The Barcelona-based company expects plasma collection to continue rising in 2022, which would reduce the blood's cost and increase Grifols' profitability, it said in a statement.